Terns Pharmaceuticals, Inc. (NASDAQ: TERN) related to its sale to Merck Sharp & Dohme LLC. Under the terms of the proposed transaction, Terns shareholders are expected to receive $53.00 per share in cash.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) related to its sale to Merck Sharp & Dohme LLC. Under the terms of the proposed transaction, Terns shareholders are expected to receive $53.00 per share in cash.